Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Ain Shams University

Status and phase: Enrolling; Phase 4

Conditions: Myocardial Infarction

Treatments: Drug: Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention; Drug: Intravenous atropine immediately before wire crossing during primary percutaneous coronary intervention

Study type: Interventional

Funder types: Other

Identifiers

NCT07268586

FMASU R49/2025

Details and patient eligibility

About

People with acute inferior wall myocardial infarction will be given an intravenous drug called atropine that increases the heart rate to check if it prevents heart rhythm disturbances during performing coronary intervention

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute inferior ST elevation myocardial infarction

Exclusion criteria

• Execution of rescur percutaneous coronary intervention after thrombolysis
• Mechanical complications or no reflow or spontaneous reperfusion.
• Prior implantation of permanent or temporary pacemakers
• History of bradycardia, hypotension or ventricular tachycardia with a definitive cause (unrelated to the disease under study)
• Prior coronary artery bypass graft surgery
• Atropine contraindications Unwillingness to participate in the

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

150 participants in 2 patient groups, including a placebo group

Atropine arm

Active Comparator group

Description:

This group will receive intravenous atropine 1 mg immediately before wire crossing

Treatment:

Drug: Intravenous atropine immediately before wire crossing during primary percutaneous coronary intervention

Placebo arm

Placebo Comparator group

Description:

This group will receive intravenous normal saline immediately before wire crossing

Treatment:

Drug: Intravenous normal saline as placebo immediately before wire crossing during primary percutaneous coronary intervention